Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

Owing to its different but proven mode of action, interleukin-2 immunotherapy could complement many anticancer approaches, including immune checkpoint inhibitors, adoptive cell transfer regimens and vaccination.